Prostate specific antigen gene regulation by androgen receptor

Prostate specific antigen (PSA) is a serine protease that is synthesized by both normal and malignant epithelial cells of the human prostate. PSA expressed by malignant cells, however, are released into the serum at an increased level, which can be detected to diagnose and monitor prostate cancer. Moreover, increases in serum PSA following local and systemic treatments are highly correlated with tumor recurrence and progression, and this association has further established PSA as a clinically important biomarker. The expression of PSA is mainly induced by androgens and regulated by the androgen receptor (AR) at the transcriptional level. Extensive research on the regulation of PSA gene expression has provided significant information about the function of AR, which is a crucial transcription factor involved in all phases of prostate cancer. Still, the molecular mechanism(s) by which the transcription of the PSA gene escapes regulation in advanced prostate cancer has yet to be clearly defined. Accumulating evidence suggests that a number of processes including androgen‐independent activation of AR are involved. Lacking an effective treatment, advanced prostate cancer is almost invariably fatal, which highlights the importance of elucidating mechanisms of tumor progression. Insights into AR activity at the PSA gene could be extended to transcriptional regulation of other AR target genes, which may be crucial in discerning prostate cancer progression. Ultimately, our improved understanding of AR‐regulated PSA expression could aid in developing viable therapies in treating and/or preventing advanced prostate cancer. © 2004 Wiley‐Liss, Inc.

[1]  D. Reinberg,et al.  Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. , 2001, Genes & development.

[2]  J. Trapman,et al.  Two Androgen Response Regions Cooperate in Steroid Hormone Regulated Activity of the Prostate-specific Antigen Promoter (*) , 1996, The Journal of Biological Chemistry.

[3]  C. Glass,et al.  Coregulator Codes of Transcriptional Regulation by Nuclear Receptors* , 2001, The Journal of Biological Chemistry.

[4]  G. Bubley,et al.  BIOLOGY OF PROSTATESPECIFIC ANTIGEN , 2003 .

[5]  E. Bleecker,et al.  Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. , 2003, Journal of the National Cancer Institute.

[6]  Stuart L. Schreiber,et al.  Active genes are tri-methylated at K4 of histone H3 , 2002, Nature.

[7]  Paul T. Tarr,et al.  Cooperative Assembly of Androgen Receptor into a Nucleoprotein Complex That Regulates the Prostate-specific Antigen Enhancer* , 1999, The Journal of Biological Chemistry.

[8]  W. Ellis,et al.  Advanced prostatic carcinoma. Early versus late endocrine therapy. , 1991, The Urologic clinics of North America.

[9]  Chawnshang Chang,et al.  Androgen Receptor Coregulators in Prostate Cancer , 2004, Clinical Cancer Research.

[10]  G. Yousef,et al.  Human tissue kallikrein gene family: a rich source of novel disease biomarkers , 2001, Expert review of molecular diagnostics.

[11]  W. Farrar,et al.  Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.

[12]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[13]  G. Coetzee,et al.  Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. , 2003, Molecular cancer research : MCR.

[14]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[15]  G. Coetzee,et al.  Genetic determinants of serum prostate-specific antigen levels in healthy men from a multiethnic cohort. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  D. Peehl,et al.  Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. , 1994, The Journal of endocrinology.

[17]  G. Coetzee,et al.  Dynamic methylation of histone H3 at lysine 4 in transcriptional regulation by the androgen receptor. , 2003, Nucleic acids research.

[18]  A. Brinkmann,et al.  Androgen receptor phosphorylation. , 1996, Endocrine research.

[19]  Chawnshang Chang,et al.  Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. , 2003, Biochemical and biophysical research communications.

[20]  E. Bleecker,et al.  Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  N. Bruchovsky,et al.  Prostate cancer: molecular biology of early progression to androgen independence. , 1999, Endocrine-related cancer.

[22]  Y. Horiguchi,et al.  Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  G. Bubley,et al.  Biology of prostate-specific antigen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Z. Hall.  Cancer , 1906, The Hospital.

[25]  H. Klocker,et al.  Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  P. Riegman,et al.  The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. , 1991, Molecular endocrinology.

[27]  Daniel Gioeli,et al.  Ras signaling in prostate cancer progression , 2004, Journal of cellular biochemistry.

[28]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[29]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[30]  G. Coetzee,et al.  Contribution of the Androgen Receptor to Prostate Cancer Predisposition and Progression , 2004, Cancer and Metastasis Reviews.

[31]  Nicholas Bruchovsky,et al.  Ligand-independent Activation of the Androgen Receptor by Interleukin-6 and the Role of Steroid Receptor Coactivator-1 in Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[32]  L. Nazareth,et al.  Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[33]  F. S. French,et al.  Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer* , 2004, Journal of Biological Chemistry.

[34]  E. Keller,et al.  Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[36]  F. Orio,et al.  Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines , 2002, Molecular and Cellular Endocrinology.

[37]  J. Isaacs,et al.  A history of prostate cancer treatment , 2002, Nature Reviews Cancer.

[38]  G. Coetzee,et al.  Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. , 2000, Cancer research.

[39]  Sandra Costa,et al.  Linkage between polymorphisms in the prostate specific antigen ARE1 gene region, prostate cancer risk, and circulating tumor cells , 2002, The Prostate.

[40]  J. Simons,et al.  Interleukin-6: a candidate mediator of human prostate cancer morbidity. , 1995, Urology.

[41]  J. Simons,et al.  Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.

[42]  S. Balk,et al.  Androgen receptor as a target in androgen-independent prostate cancer. , 2002, Urology.

[43]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[44]  D. Tindall,et al.  p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. , 2002, Cancer research.

[45]  Wei Xu,et al.  Androgen-induced recruitment of RNA polymerase II to a nuclear receptor–p160 coactivator complex , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R A Irvine,et al.  Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. , 2000, Cancer research.